International Journal of Experimental and Biomedical Research最新文献

A comparative study of efficacy and safety in stage I hypertensive patients visiting the cardiac OPD at a tertiary care hospital 一家三级医院心脏手术室 I 期高血压患者疗效和安全性比较研究

International Journal of Experimental and Biomedical Research Pub Date : 2024-02-09 DOI: 10.26452/ijebr.v3i1.582

Kishore Bandarapalle, Chandu Priya Kanta, Thulasi Eduga, Soumya Gunthanakkala, Snehalatha Vaddi, Hari Deepika Manige, Sravani Narasapuram

{"title":"A comparative study of efficacy and safety in stage I hypertensive patients visiting the cardiac OPD at a tertiary care hospital","authors":"Kishore Bandarapalle, Chandu Priya Kanta, Thulasi Eduga, Soumya Gunthanakkala, Snehalatha Vaddi, Hari Deepika Manige, Sravani Narasapuram","doi":"10.26452/ijebr.v3i1.582","DOIUrl":"https://doi.org/10.26452/ijebr.v3i1.582","url":null,"abstract":"To investigate the efficacy and safety of Azilsartan 40 mg and Olmesartan 40 mg in patients with stage I systemic hypertension undergoing cardiac OPD at a tertiary care facility. A 6-month open-label comparison study was undertaken in the Department of Cardiology at Acsr Government Medical College and Hospital. All patients visiting the cardiac outpatient clinic at Acsr Government Medical College who have stage I systemic hypertension of any sex, aged 20-65, with blood pressures >140/90 mmHg, or glucose intolerance. Diagnoses for essential hypertension were made, and patients were randomised to receive either group 1 (40 mg of Azilsartan) or group 2 (40 mg of Olmesartan) after the initial screening. The individuals receiving care were instructed to come back for a fourth, eighth, twelveth, as well as twenty-fourth weeks. Both groups showed a statistically significant drop in systolic blood pressure (P value < 0.0000001). Both medicines regulated blood pressure in similar ways. However, the Azilsartan group had a lower mean SBP and DBP than the Olmesartan group. Both medicines were well tolerated, and no severe side effects were observed throughout the research.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":" 39","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139790798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comparative study of efficacy and safety in stage I hypertensive patients visiting the cardiac OPD at a tertiary care hospital 一家三级医院心脏手术室 I 期高血压患者疗效和安全性比较研究

International Journal of Experimental and Biomedical Research Pub Date : 2024-02-09 DOI: 10.26452/ijebr.v3i1.582

Kishore Bandarapalle, Chandu Priya Kanta, Thulasi Eduga, Soumya Gunthanakkala, Snehalatha Vaddi, Hari Deepika Manige, Sravani Narasapuram

{"title":"A comparative study of efficacy and safety in stage I hypertensive patients visiting the cardiac OPD at a tertiary care hospital","authors":"Kishore Bandarapalle, Chandu Priya Kanta, Thulasi Eduga, Soumya Gunthanakkala, Snehalatha Vaddi, Hari Deepika Manige, Sravani Narasapuram","doi":"10.26452/ijebr.v3i1.582","DOIUrl":"https://doi.org/10.26452/ijebr.v3i1.582","url":null,"abstract":"To investigate the efficacy and safety of Azilsartan 40 mg and Olmesartan 40 mg in patients with stage I systemic hypertension undergoing cardiac OPD at a tertiary care facility. A 6-month open-label comparison study was undertaken in the Department of Cardiology at Acsr Government Medical College and Hospital. All patients visiting the cardiac outpatient clinic at Acsr Government Medical College who have stage I systemic hypertension of any sex, aged 20-65, with blood pressures >140/90 mmHg, or glucose intolerance. Diagnoses for essential hypertension were made, and patients were randomised to receive either group 1 (40 mg of Azilsartan) or group 2 (40 mg of Olmesartan) after the initial screening. The individuals receiving care were instructed to come back for a fourth, eighth, twelveth, as well as twenty-fourth weeks. Both groups showed a statistically significant drop in systolic blood pressure (P value < 0.0000001). Both medicines regulated blood pressure in similar ways. However, the Azilsartan group had a lower mean SBP and DBP than the Olmesartan group. Both medicines were well tolerated, and no severe side effects were observed throughout the research.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":"125 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139850365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Formulation and evaluation of voriconazole nanocapsules 伏立康唑纳米胶囊的制备与评估

International Journal of Experimental and Biomedical Research Pub Date : 2024-02-01 DOI: 10.26452/ijebr.v3i1.565

Subba Rao G, Sowmy Adapa

{"title":"Formulation and evaluation of voriconazole nanocapsules","authors":"Subba Rao G, Sowmy Adapa","doi":"10.26452/ijebr.v3i1.565","DOIUrl":"https://doi.org/10.26452/ijebr.v3i1.565","url":null,"abstract":"The current study's goal was to create as well as assess voriconazole nanocapsules using the diffusion of emulsion solvent technology. Voriconazole was made using the emulsion solvent diffusion method and is loaded with ethyl cellulose and HPMC Nanocapsules. The FTIR data showed that there was no drug-polymer interaction and that voriconazole nanocapsules filled with ethyl cellulose were stable. The absence of incompatibility in the formulation was investigated using compatability investigations such as FTIR and DSC. SEM is used to determine the morphological particle size of the voriconazole nanocapsules. F1 through F8 are the complete formulation codes for which the nanocapsules were tested. A percentage yield of 83.32% to 88.61% was discovered. There was 65.8 to 98.5% drug content. The nanocapsules' particle size ranged from 78 µm to 33 µm, while their drug entrapment effectiveness ranged from 54.4% to 91.4% and their drug loading capacity from 56.8% to 97.7%. The study period for swellability was 0.8 to 1.5 seconds. The optimal formulation, F8, showed an in vitro dissolving rate of 61.89%. Numerous mathematical models, including zero order, first order, Higuchi matrix, and Korsmeyer Peppas model, were fitted to the available data on drug dissolution in vitro. The R2 value and m value of the Voriconazole Nanocapsules model were 0.937, 0.399, 0.899, 0.785, and 2.560, respectively. Up to 45 mints of medication were released from the nanocapsules. The HPMC and ethyl cellulose-loaded Voriconazole nanocapsules were made under ideal circumstances and have good release properties.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":"35 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139816423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Formulation and evaluation of voriconazole nanocapsules 伏立康唑纳米胶囊的制备与评估

International Journal of Experimental and Biomedical Research Pub Date : 2024-02-01 DOI: 10.26452/ijebr.v3i1.565

Subba Rao G, Sowmy Adapa

{"title":"Formulation and evaluation of voriconazole nanocapsules","authors":"Subba Rao G, Sowmy Adapa","doi":"10.26452/ijebr.v3i1.565","DOIUrl":"https://doi.org/10.26452/ijebr.v3i1.565","url":null,"abstract":"The current study's goal was to create as well as assess voriconazole nanocapsules using the diffusion of emulsion solvent technology. Voriconazole was made using the emulsion solvent diffusion method and is loaded with ethyl cellulose and HPMC Nanocapsules. The FTIR data showed that there was no drug-polymer interaction and that voriconazole nanocapsules filled with ethyl cellulose were stable. The absence of incompatibility in the formulation was investigated using compatability investigations such as FTIR and DSC. SEM is used to determine the morphological particle size of the voriconazole nanocapsules. F1 through F8 are the complete formulation codes for which the nanocapsules were tested. A percentage yield of 83.32% to 88.61% was discovered. There was 65.8 to 98.5% drug content. The nanocapsules' particle size ranged from 78 µm to 33 µm, while their drug entrapment effectiveness ranged from 54.4% to 91.4% and their drug loading capacity from 56.8% to 97.7%. The study period for swellability was 0.8 to 1.5 seconds. The optimal formulation, F8, showed an in vitro dissolving rate of 61.89%. Numerous mathematical models, including zero order, first order, Higuchi matrix, and Korsmeyer Peppas model, were fitted to the available data on drug dissolution in vitro. The R2 value and m value of the Voriconazole Nanocapsules model were 0.937, 0.399, 0.899, 0.785, and 2.560, respectively. Up to 45 mints of medication were released from the nanocapsules. The HPMC and ethyl cellulose-loaded Voriconazole nanocapsules were made under ideal circumstances and have good release properties.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":"1 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139876208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review Study on Safety and Efficacy on Second Line Anti Tubercular Drugs 二线抗结核药物的安全性和有效性回顾研究

International Journal of Experimental and Biomedical Research Pub Date : 2023-08-23 DOI: 10.26452/ijebr.v2i3.538

Motimi Sreelatha, Bachu Naveena, Y. P. Chandra

{"title":"A Review Study on Safety and Efficacy on Second Line Anti Tubercular Drugs","authors":"Motimi Sreelatha, Bachu Naveena, Y. P. Chandra","doi":"10.26452/ijebr.v2i3.538","DOIUrl":"https://doi.org/10.26452/ijebr.v2i3.538","url":null,"abstract":"Due to intestinal dysbiosis brought on by second-line anti-tubercular medication therapy, the patient's resistance to MTB appears to have decreased. This is likely due to an impact on immune cell proliferation and autophagic processes. therefore adversely influencing the patients' treatment results. The objectives of review articles are the safety and efficacy on the second line anti tubercular drugs. The results of these review article in the year 2015 to 2020. The conversation of these review article is the safety and efficacy of second line anti tubercular drugs . The discussion of these study about the safety and efficacy on second line anti tubercular drugs . 2016 levofloxacin is a not more safe and less effective because result insufficient control to the tuberculosis patient it adverse events is underactive thyroid. 2020 Ethionamide is a safe and effective for the TB patients. The conclusion of these review study and efficacy of the second line anti tubercular drugs. The ofloxacin are the most effective and safe when compared to the other second line anti tubercular drugs. In second line anti tubercular drugs the levofloxacin is having the less efficacy when compared to other second line anti tubercular drugs because it is having the adverse effect of the hypothyroidism. For the treatment of tuberculosis the drugs used are the levofloxacin, kanamycin, etc and these are most commonly used for the prevention of the disease.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139349498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilising the Ethanolic Extracts of Leaves Garcinia Cambogia and Commiphora Mukul Herbal Pills Prepared for Treating Anti-Obesity Effects 利用黄藤叶乙醇提取物和金缕草抗肥胖的研究

International Journal of Experimental and Biomedical Research Pub Date : 2023-03-31 DOI: 10.26452/ijebr.v2i1.484

Chandana Pasupuleti, Chimata Manisha

{"title":"Utilising the Ethanolic Extracts of Leaves Garcinia Cambogia and Commiphora Mukul Herbal Pills Prepared for Treating Anti-Obesity Effects","authors":"Chandana Pasupuleti, Chimata Manisha","doi":"10.26452/ijebr.v2i1.484","DOIUrl":"https://doi.org/10.26452/ijebr.v2i1.484","url":null,"abstract":"A complex disorder called obesity is characterised by an excessive quantity of bodily fat. It raises the risk of developing other illnesses and medical conditions like diabetes, high blood pressure, and heart conditions. When our BMI is 30kg/m2 or greater, obesity is considered to exist. Today, more ailments are treated with traditional medicines—mostly herbal in nature—than with allopathic drugs. Compared to herbal drugs, allopathic drugs have higher side effects. The purpose of the current work is to create and assess the herbal tablet prepared using an ethanolic extract of Commiphoramukul and Garcinia cambogia leaves. Wet granulation was used to manufacture the formulation. Both the pre-compression parameter and the post-compression parameter of the prepared formulation were assessed. The calculation demonstrated that the permissible pre- and post-compression parameter is within bounds. Before and after the IEC's stability investigation, the Garcinia cambogia (HCA) content assay yielded results of 49.78% and 49.69%, respectively (Ion Exchange Chromatography). The content of Commiphoramukul (guggulsterones) was 12.38% and 12.26% before and after the UV Spectrophotometer stability investigation. The formulation was found to be reasonably stable based on the findings.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126966046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Test-next 方法

International Journal of Experimental and Biomedical Research Pub Date : 2022-03-28 DOI: 10.26452/ijebr.v1i1.366

Neelam Injeti

引用次数: 0

Test 测试

International Journal of Experimental and Biomedical Research Pub Date : 2022-01-28 DOI: 10.26452/ijebr.v1i1.359

P. S.

引用次数: 0

Test-1 测试1

International Journal of Experimental and Biomedical Research Pub Date : 2022-01-19 DOI: 10.26452/ijebr.v1i1.361

P. S.

引用次数: 0